HSK3486 + Propofol

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Colonoscopy

Conditions

Colonoscopy

Trial Timeline

Dec 1, 2016 → Jun 1, 2017

NCT ID

NCT03773042

About HSK3486 + Propofol

HSK3486 + Propofol is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Colonoscopy. The current trial status is completed. This product is registered under clinical trial identifier NCT03773042. Target conditions include Colonoscopy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04669821	Phase 2	Completed	Mar 9, 2021	Oct 9, 2021	Sedation in Intensive Care
NCT04620031	Phase 3	Completed	Dec 8, 2020	Aug 17, 2021	Sedation in Intensive Care
NCT04511728	Phase 3	Completed	Nov 24, 2020	Jan 25, 2021	Induction and Maintenance of General Anesthesia
NCT04111159	Phase 3	Completed	Dec 6, 2019	Jul 27, 2020	Sedation or Anesthesia
NCT03808844	Phase 3	Completed	Mar 22, 2019	Sep 3, 2019	Induction of Anesthesia
NCT03745625	Phase 1	Completed	Jan 9, 2019	Aug 27, 2019	Anesthesia
NCT03674008	Phase 3	Completed	Oct 9, 2018	Mar 10, 2019	Sedation or Anesthesia
NCT03709056	Phase 2	Completed	Dec 14, 2017	Aug 9, 2018	Sedation and Anesthesia for Adult Colonoscopy Procedures
NCT03698617	Phase 2	Completed	Dec 6, 2016	Jul 18, 2018	Induction of General Anaesthesia
NCT03773042	Phase 2	Completed	Dec 1, 2016	Jun 1, 2017	Colonoscopy
NCT04037657	Phase 1	Completed	Apr 22, 2015	Nov 13, 2015	Anesthesia

Competing Products

7 competing products in Colonoscopy

See all competitors

Product	Company	Stage	Hype Score
fospropofol disodium	Eisai	Phase 3	77
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCl	Eisai	Phase 2/3	65
fospropofol disodium	Eisai	Phase 2	52
fospropofol disodium	Eisai	Phase 2	52
HSK3486 + Propofol	Haisco Pharmaceutical Group	Phase 2	49
Methylene Blue MMX 25 mg modified release tablets	Cosmo Pharmaceuticals	Phase 2	47
Polyethylene glycol 4000 + Macrogol 3350 plus ascorbic acid	Rafael Holdings	Approved	77

Other Products from Haisco Pharmaceutical Group

Crisugabalin + PlaceboApproved

Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDApproved

Cyclopofol + PropofolApproved

Ciprofol + PropofolApproved

CipepofolApproved